This week, the ratings of 19 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Teva Pharmaceutical Industries Limited Sponsored ADR’s (TEVA) rating worsens to a D from the company’s C rating a week ago. Teva Pharmaceutical Industries Limited Sponsored ADR is engaged in the provision of pharmaceutical services. For more information, get Portfolio Grader’s complete analysis of TEVA stock.

Slipping from a C to a D rating, Merck & Co., Inc. (MRK) takes a hit this week. Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MRK stock.

Pacira Pharmaceuticals, Inc. (PCRX) gets weaker ratings this week as last week’s D drops to a F. Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. The company also gets F’s in earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PCRX stock.

Mylan N.V. (MYL) earns a D this week, moving down from last week’s grade of C. Mylan N.V. is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.

GlaxoSmithKline plc Sponsored ADR (GSK) declines this week from a C to a D. GlaxoSmithKline plc Sponsored ADR is a research-based pharmaceutical company. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of GSK stock.

Sanofi Sponsored ADR (SNY) is having a tough week. The company’s rating falls from a C to a D. Sanofi Sponsored ADR is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. For more information, get Portfolio Grader’s complete analysis of SNY stock.

ANI Pharmaceuticals, Inc.’s (ANIP) rating weakens this week, dropping to a F versus last week’s D. ANI Pharmaceuticals, Inc. develops, manufactures, and markets prescription and over-the-counter pharmaceuticals. The company also gets F’s in sales growth, earnings growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ANIP stock.

This is a rough week for Impax Laboratories, Inc. (IPXL). The company’s rating falls to D from the previous week’s C. Impax Laboratories, Inc. develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of IPXL stock.

This week, Astrazeneca PLC Sponsored ADR (AZN) drops from a C to a D rating. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. For more information, get Portfolio Grader’s complete analysis of AZN stock.

Cempra, Inc. (CEMP) experiences a ratings drop this week, going from last week’s D to a F. Cempra, Inc. manufactures and markets pharmaceutical products. The company also gets F’s in sales growth, earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of CEMP stock.

Teligent, Inc. (TLGT) slips from a C to a D this week. The company also gets F’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of TLGT stock.

XenoPort, Inc. (XNPT) declines this week from a C to a D. XenoPort, Inc. is a biopharmaceutical company that focuses on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company also gets F’s in sales growth, earnings growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of XNPT stock.

This week, Evoke Pharma, Inc.’s (EVOK) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EVOK stock.

Tetraphase Pharmaceuticals, Inc. (TTPH) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TTPH stock.

Aralez Pharmaceuticals Inc.’s (ARLZ) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in sales growth, operating margin growth, earnings growth, earnings revisions, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARLZ stock.

Ocera Therapeutics, Inc. (OCRX) earns a D this week, moving down from last week’s grade of C. Ocera Therapeutics, Inc. develops novel therapeutics products designed to treat liver and gastrointestinal diseases. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OCRX stock.

This week, Parnell Pharmaceuticals Holdings Ltd. (PARN) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PARN stock.

Novogen Limited Sponsored ADR (NVGN) gets weaker ratings this week as last week’s C drops to a D. Novogen Limited Sponsored ADR is a medical services company which develops and markets pharmaceutical products in Australia. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVGN stock.

BioPharmX Corp. (BPMX) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BPMX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.